Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2026-02-05 00:00:00 ET · period of report 2026-02-03 · accession 0001957554-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-05 | 2026-02-03 | ACRS | Balthaser Kevin | CFO | M - OptEx | — | +22.0K | 192.2K | +13% | — |
| D | 2026-02-05 | 2026-02-03 | ACRS | Balthaser Kevin | CFO | F - Tax | $3.47 | -6,449 | 185.8K | -3% | -$22.4K |
| D | 2026-02-05 | 2026-02-03 | ACRS | Balthaser Kevin | CFO | M - OptEx | $0.00 | -22.0K | 66.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-03 | M | A | 22,025 | — | 192,204 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Common | Common Stock | 2026-02-03 | F | D | 6,449 | $3.47 | 185,755 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-02-03 | M | D | 22,025 | $0.00 | 66,075 | D | — · — to — | 22,025 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |